These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 16006965)

  • 1. C-jun activation in acquired cystic kidney disease and renal cell carcinoma.
    Oya M; Mikami S; Mizuno R; Marumo K; Mukai M; Murai M
    J Urol; 2005 Aug; 174(2):726. PubMed ID: 16006965
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Image analysis of proliferating cell nuclear antigen expression and immunohistochemical profiles in renal cell carcinoma associated with acquired cystic kidney disease: comparison with classic renal cell carcinoma.
    Khurana KK; Truong LD; Verani RR
    Mod Pathol; 1998 Apr; 11(4):339-46. PubMed ID: 9578084
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Over expression of hypoxia-inducible protein 2, hypoxia-inducible factor-1alpha and nuclear factor kappaB is putatively involved in acquired renal cyst formation and subsequent tumor transformation in patients with end stage renal failure.
    Konda R; Sugimura J; Sohma F; Katagiri T; Nakamura Y; Fujioka T
    J Urol; 2008 Aug; 180(2):481-5. PubMed ID: 18550099
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Renal cell carcinoma co-existent with other renal disease: clinico-pathological features in pre-dialysis patients and those receiving dialysis or renal transplantation.
    Peces R; Martínez-Ara J; Miguel JL; Arrieta J; Costero O; Górriz JL; Picazo ML; Fresno M
    Nephrol Dial Transplant; 2004 Nov; 19(11):2789-96. PubMed ID: 15316098
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Presence of phosphorylated hepatocyte growth factor receptor/c-Met is associated with tumor progression and survival in patients with conventional renal cell carcinoma.
    Miyata Y; Kanetake H; Kanda S
    Clin Cancer Res; 2006 Aug; 12(16):4876-81. PubMed ID: 16914575
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinicopathological features and CD57 expression in renal cell carcinoma in acquired cystic disease of the kidneys: with special emphasis on a relation to the duration of haemodialysis, the degree of calcium oxalate deposition, histological type, and possible tumorigenesis.
    Enoki Y; Katoh G; Okabe H; Yanagisawa A
    Histopathology; 2010 Feb; 56(3):384-94. PubMed ID: 20459538
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mutant p53 expression in kidney tubules adjacent to renal cell carcinoma: evidence of a precursor lesion.
    Lai R; el Dabbagh L; Mourad WA
    Mod Pathol; 1996 Jun; 9(6):690-5. PubMed ID: 8782209
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Differential expression of activator protein-2 isoforms in renal cell carcinoma.
    Oya M; Mikami S; Mizuno R; Miyajima A; Horiguchi Y; Nakashima J; Marumo K; Mukai M; Murai M
    Urology; 2004 Jul; 64(1):162-7. PubMed ID: 15245963
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cytologic findings of acquired cystic disease-associated renal cell carcinoma: a report of two cases.
    Rivera M; Tickoo SK; Saqi A; Lin O
    Diagn Cytopathol; 2008 May; 36(5):344-7. PubMed ID: 18418849
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Activation of mTOR in renal cell carcinoma is due to increased phosphorylation rather than protein overexpression.
    Kruck S; Bedke J; Hennenlotter J; Ohneseit PA; Kuehs U; Senger E; Sievert KD; Stenzl A
    Oncol Rep; 2010 Jan; 23(1):159-63. PubMed ID: 19956876
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Analysis of the expression of HLA class I, proinflammatory cytokines and chemokines in primary tumors from patients with localized and metastatic renal cell carcinoma.
    Romero JM; Aptsiauri N; Vazquez F; Cozar JM; Canton J; Cabrera T; Tallada M; Garrido F; Ruiz-Cabello F
    Tissue Antigens; 2006 Oct; 68(4):303-10. PubMed ID: 17026465
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Renal-cell carcinomas in end-stage kidneys: a clinicopathological study with emphasis on clear-cell papillary renal-cell carcinoma and acquired cystic kidney disease-associated carcinoma.
    Bhatnagar R; Alexiev BA
    Int J Surg Pathol; 2012 Feb; 20(1):19-28. PubMed ID: 21791489
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Atypical cysts, acquired renal cystic disease, and renal cell tumors in end stage dialysis kidneys.
    Hughson MD; Hennigar GR; McManus JF
    Lab Invest; 1980 Apr; 42(4):475-80. PubMed ID: 7374111
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic significance of tenascin-C expression in clear cell renal cell carcinoma.
    Ohno Y; Izumi M; Yoshioka K; Ohori M; Yonou H; Tachibana M
    Oncol Rep; 2008 Sep; 20(3):511-6. PubMed ID: 18695899
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Acquired cystic kidney disease-associated renal cell carcinoma: a clinicopathologic study of three cases].
    Zhang W; Xu LL; Yu WJ; Wang Q; Jiang YX; Liu Y; Li YJ
    Zhonghua Bing Li Xue Za Zhi; 2018 May; 47(5):366-371. PubMed ID: 29783804
    [No Abstract]   [Full Text] [Related]  

  • 16. Renal papillary adenoma--a putative precursor of papillary renal cell carcinoma.
    Wang KL; Weinrach DM; Luan C; Han M; Lin F; Teh BT; Yang XJ
    Hum Pathol; 2007 Feb; 38(2):239-46. PubMed ID: 17056094
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Significance of Fas expression alteration during tumor progression of renal cell carcinoma.
    Sejima T; Miyagawa I
    Int J Urol; 2006 Mar; 13(3):257-64. PubMed ID: 16643620
    [TBL] [Abstract][Full Text] [Related]  

  • 18. BIGH3 is overexpressed in clear cell renal cell carcinoma.
    Yamanaka M; Kimura F; Kagata Y; Kondoh N; Asano T; Yamamoto M; Hayakawa M
    Oncol Rep; 2008 Apr; 19(4):865-74. PubMed ID: 18357369
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Morphoproteomic and molecular concomitants of an overexpressed and activated mTOR pathway in renal cell carcinomas.
    Lin F; Zhang PL; Yang XJ; Prichard JW; Lun M; Brown RE
    Ann Clin Lab Sci; 2006; 36(3):283-93. PubMed ID: 16951269
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Increased activation of CCAAT/enhancer binding protein-beta correlates with the invasiveness of renal cell carcinoma.
    Oya M; Horiguchi A; Mizuno R; Marumo K; Murai M
    Clin Cancer Res; 2003 Mar; 9(3):1021-7. PubMed ID: 12631601
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.